Relatively little is known about the dietary and lifestyle factors that influence survival after a diagnosis of colorectal cancer. In fact, a consensus panel of the American Cancer Society recommended, "Properly conducted studies of the effect of nutrition and physical activity on the prognosis of cancer survivors are urgently needed, and should be a high priority for all academic and research funding agencies." Many of the nutritional and lifestyle factors that are thought to influence colorectal cancer progression (low vitamin D, high insulin, obesity, and physical inactivity) may operate through the vitamin D, inflammatory, and energy balance pathways in the cell. Elucidating the biological explanation for the link between these factors and colorectal cancer would enhance the acceptability of nutrition and exercise as critical for cancer treatment. To address this problem, the current proposal focuses on the investigation of biochemical, genetic, and dietary predictors of colorectal cancer recurrence and survival, with the ultimate goal of reducing mortality. Three inter-related pathways will be studied.
For Aim 1, we will examine plasma levels of vitamin D, a vitamin D prediction score, and genetic variation within the pathway, and how these exposures interact with specific molecular alterations.
For Aim 2, we will investigate plasma markers of inflammation and genetic variation in inflammation-related genes, in an effort to better understand the link between chronic inflammation and colorectal cancer. In addition, we will explore the interaction between these inflammatory markers and the vitamin D pathway.
For Aim 3, we will examine a novel dietary index that estimates long-term systemic insulin exposure, as well as the relationship between members of the insulin-like growth factor pathway and vitamin D. A major strength of this proposal is the ability to examine these plasma, genetic, and dietary factors prospectively, using three large cohorts of colorectal cancer patients with repeated dietary and lifestyle assessments;archived blood, tumor, and DNA specimens;and comprehensive data on prognostic factors and cancer outcomes. By examining these aims, this project will improve the understanding of the mechanisms that underlie colorectal cancer pathogenesis and define practical treatment measures for this difficult disease. Moreover, the current proposal will allow the candidate to gain advanced skills in biostatistics and epidemiology, pursue a focused program in colorectal cancer research, and receive close, long-term mentorship from experienced and successful investigators, promoting her transition to an independent academic researcher. The intense collaboration and vast resources of the Dana-Farber/Harvard Cancer Center, Channing Laboratory, and Harvard School of Public Health provide an ideal environment for the candidate to receive the training and mentorship needed to become a leader in the field of cancer research.

Public Health Relevance

Although colorectal cancer is the second leading cause of cancer death in the United States, relatively little is known about the dietary and lifestyle factors that influence cancer survival. Many of these modifiable factors may operate through the vitamin D, inflammatory, and energy balance pathways in the cell. The current proposal hopes to advance the understanding of colorectal cancer pathogenesis by examining potential biochemical, genetic, and dietary predictors of outcome in these pathways, with the ultimate goal of optimizing treatment strategies and improving prognosis in patients with this lethal disease.

National Institute of Health (NIH)
Academic/Teacher Award (ATA) (K07)
Project #
Application #
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Perkins, Susan N
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Ng, Kimmie (2014) Vitamin D for Prevention and Treatment of Colorectal Cancer: What is the Evidence? Curr Colorectal Cancer Rep 10:339-345
Chandler, Paulette D; Scott, Jamil B; Drake, Bettina F et al. (2014) Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D. Am J Med 127:772-8
Jung, Seungyoun; Qian, Zhi Rong; Yamauchi, Mai et al. (2014) Predicted 25(OH)D score and colorectal cancer risk according to vitamin D receptor expression. Cancer Epidemiol Biomarkers Prev 23:1628-37
Ng, Kimmie; Scott, Jamil B; Drake, Bettina F et al. (2014) Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial. Am J Clin Nutr 99:587-98
Chandler, Paulette D; Scott, Jamil B; Drake, Bettina F et al. (2014) Impact of vitamin D supplementation on inflammatory markers in African Americans: results of a four-arm, randomized, placebo-controlled trial. Cancer Prev Res (Phila) 7:218-25
Rubinson, Douglas A; Hochster, Howard S; Ryan, David P et al. (2014) Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs 32:113-22
Hiraki, Linda T; Joshi, Amit D; Ng, Kimmie et al. (2014) Joint effects of colorectal cancer susceptibility loci, circulating 25-hydroxyvitamin D and risk of colorectal cancer. PLoS One 9:e92212
Chandler, Paulette D; Giovannucci, Edward L; Scott, Jamil B et al. (2014) Null association between vitamin D and PSA levels among black men in a vitamin D supplementation trial. Cancer Epidemiol Biomarkers Prev 23:1944-7
Wolpin, Brian M; Ng, Kimmie; Zhu, Andrew X et al. (2013) Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist 18:377-8
Ng, Kimmie; Tabernero, Josep; Hwang, Jimmy et al. (2013) Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. Clin Cancer Res 19:3987-95

Showing the most recent 10 out of 15 publications